Epithalon (Epitalon) is a synthetic pineal-gland (epiphysis) peptide that remains one of the most discussed subjects in gerontology research. This review explains what epithalon is, which of its properties scientists study, what the protocols in experiments looked like, and why the name of Professor Vladimir Khavinson is inseparable from this molecule. The material is purely educational and concerns compounds intended for research use.
What epithalon is, and why it is a "pineal peptide"
Epithalon (also Epitalon, Epithalone, AEDG) is a short tetrapeptide with the sequence alanine-glutamic acid-aspartic acid-glycine (Ala-Glu-Asp-Gly). It was synthesized as an analog of natural epithalamin, a peptide extract of the pineal gland. This is why epithalon is often called a "pineal peptide": it reproduces the structural idea of the regulatory molecules of the pineal gland, which in the body governs melatonin production and the synchronization of circadian rhythms.
Epithalon properties under study
Scientific interest in epithalon's properties centers on several directions. Research models have described:
- Circadian-rhythm regulation. Researchers examined the peptide's ability to influence melatonin secretion and to normalize the sleep-wake cycle, especially in older model organisms.
- Antioxidant activity. Experiments noted reductions in markers of oxidative stress.
- Telomerase activity. The most prominent line of work: the ability to induce the enzyme telomerase in cultures of human somatic cells, which is associated with telomere length.
- Peptide bioregulation. Epithalon is classed among short peptide bioregulators that, per the hypothesis, interact with DNA and influence gene expression.
Important: all of these properties are described in a research context, not a clinical-therapeutic one. This does not imply proven medical efficacy.
Khavinson's research
A substantial part of the data on epithalon came from the group of Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, where the concept of peptide bioregulators was developed. Work from this school described the induction of telomerase in human somatic cells. An early-2000s publication became one of the most cited in the field. Animal experiments reported effects on lifespan, the incidence of spontaneous tumors, and the state of antioxidant systems. There were also observations in elderly people, assessing melatonin dynamics and some age-related markers.
These works laid the foundation of an entire field, yet many were carried out on small samples and require independent replication. Epithalon is therefore best regarded as a promising object of study rather than a finished remedy.
What exactly was studied
In the primary literature epithalon appears with specific cellular endpoints, not as a household supplement. A 2025 review in the International Journal of Molecular Sciences systematises preclinical and cell data on the bioactivity of the AEDG tetrapeptide [1]. A 2003 paper in the Bulletin of Experimental Biology and Medicine, from the Khavinson group, described induction of telomerase activity and telomere elongation in a culture of human somatic cells under set conditions [2]. The review shows which hypotheses were tested; the second paper describes one cell model with its own concentrations and exposure time. An in vitro result does not transfer to a vial dose or a ready human protocol.
The question of "reviews" and telomere promises
Epithalon attracts many loud claims: "lengthens telomeres," "stops aging," "rejuvenates." The primary data do not prove any of that. Inducing telomerase in a cell culture under set conditions is not clinical rejuvenation of a person, and anonymous "reviews" say nothing about the quality of a specific batch. We do not publish other people's testimonials about the effect: for a researcher the firmer basis is the published endpoints and the verified identity of the compound, not forum experience.
Regimen data: where it is collected
In Khavinson's work and later studies epithalon was used in courses in animal and cell models; the specific doses, course length and frequency varied between protocols. We do not carry them into the article as instruction, the data are collected in the reference Epithalon: dosing reference.
Epithalon and modern longevity peptides
We supply epithalon as a research substance; batches come with an independent COA in an open archive. If you are interested in the broader "longevity peptide" direction, look at adjacent compounds: Pinealon, another short peptide from the Khavinson school; SS-31 for the mitochondrial direction; and NAD⁺ for cellular energy metabolism and sirtuins. The purity of each compound can be checked against its COA before research.
In short, epithalon has a long research history as a synthetic pineal peptide, largely thanks to the Khavinson school. Its properties (from melatonin regulation to telomerase activity) are intriguing but remain a subject of scientific study. Treat it as an object for research use, not a medicine.
Longeva supplies epithalon as a research substance; batches come with an independent COA, see the product page.
Sources
- Overview of Epitalon: Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062691
- Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bulletin of Experimental Biology and Medicine. 2003. doi:10.1023/A:1025493705728
The full list of sources with links, is in the monograph: Epitalon.
